Evidence map›Paper›PMID 40665591›Full record

ArticleMedical physics2025

Impact of intracellular radionuclide distribution in a Monte Carlo biophysical 3D multi-cellular model for targeted alpha therapy.

Victor Levrague, Mario Alcocer-Ávila, Sarah Leilla Otmani, Lydia Maigne, Etienne Testa, Michaël Beuve, Rachel Delorme

Abstract read
In one paragraph

Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victor LevragueUniversité Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, Grenoble, France.
Mario Alcocer-ÁvilaUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, UMR5822, Villeurbanne, France.
Sarah Leilla OtmaniUniversité Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, Grenoble, France.
Lydia MaigneUniversité Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France.
Etienne TestaUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, UMR5822, Villeurbanne, France.
Michaël BeuveUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS/IN2P3, IP2I Lyon, UMR5822, Villeurbanne, France.
Rachel DelormeUniversité Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, Grenoble, France.

Funding

ITMO Cancer AVIESAN - PCSI program 20CP176-00LabEx PRIMES (PRIMES) ANR-11-LABX-0063
6 · The paper itself

Abstract

backgroundTo understand and predict the therapeutic efficacy of targeted alpha therapy (TAT), nano- and microdosimetry are needed to consider the very heterogeneous dose deposition at cellular and subcellular levels. PURPOSE: The objective of this study is to theoretically evaluate the importance of cell internalization of alpha-emitters on relevant dosimetric and biological endpoints.

methodsIsolated cells and realistic 3D multi-cellular geometries (spheroids modeled with CPOP) were generated as well as distributions of alpha-emitters corresponding to various cellular internalization cases. The alpha particles emitted were tracked with Geant4 (Monte Carlo) simulations. We calculated mean specific energies deposited into each cell nucleus (

resultsFor a given activity per cell (APC), the radionuclide distribution had a critical influence on

conclusionsAccording to these findings, a precise modeling of alpha-emitter intracellular distributions may be required for small micro-metastases or tumors presenting regions with relatively low radionuclide concentration in order to limit the prediction uncertainties on biological outputs. Intratumoral fluctuations of APC were also found to be a critical parameter to consider for therapeutic efficacy prediction in TAT.

Indexed as

Alpha ParticlesIntracellular SpaceModels, BiologicalMonte Carlo MethodRadioisotopesCell SurvivalHumansSpheroids, CellularRadioisotopesbiophysical modelingintracellular radionuclide distributionmicrodosimetryMonte Carlo simulationstargeted alpha therapytumor control probability

Identifiers

PMID40665591
PMCPMC12264412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.